InvestorsHub Logo
Followers 466
Posts 26936
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 81

Monday, 06/27/2011 9:03:57 AM

Monday, June 27, 2011 9:03:57 AM

Post# of 797
7:17AM On The Wires (WIRES) :

Sangamo BioSciences (SGMO) announced the publication of a preclinical study demonstrating permanent functional correction of the gene that causes hemophilia B by the systemic delivery of zinc finger nucleases. The study, published in Nature, represents a significant advance in the development and systemic delivery of ZFP Therapeutics and proof of concept for ZFN-based gene-editing for the treatment of hemophilia and other monogenic diseases.


surf's up......crikey



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SGMO News